Kanilad Os

Lacosamide, the active ingredient in Kanilad Os, is a sodium channel blocker presented as an oral tablet for oral use. It is indicated for the treatment of partial‑onset seizures in patients with epilepsy.

GNH USA supplies Kanilad Os as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Lacosamide is an antiepileptic drug that acts on neuronal sodium channels to control seizure activity.

- Partial‑onset seizures: reduces the frequency and severity of focal seizures. - Epilepsy: provides adjunctive therapy for patients with focal epilepsy. - Refractory focal epilepsy: improves seizure control when other treatments are insufficient.

Lacosamide may cause a range of adverse reactions, varying from mild to serious.

Common Side Effects: - Dizziness: sensation of light‑headedness or unsteadiness. - Nausea: feeling of stomach upset or urge to vomit. - Fatigue: unusual tiredness or lack of energy. - Headache: mild to moderate pain in the head.

Serious or Rare Side Effects: - Stevens‑Johnson syndrome: severe skin reaction requiring immediate medical attention. - Cardiac arrhythmia: abnormal heart rhythm that may be life‑threatening. - Suicidal ideation: thoughts of self‑harm that need urgent evaluation. - Severe skin reactions: including toxic epidermal necrolysis. - Hypersensitivity: allergic reactions such as rash, swelling, or breathing difficulty.

Before prescribing lacosamide, clinicians should consider several safety aspects.

- Cardiac monitoring: assess ECG for PR‑interval prolongation. - Renal function: evaluate kidney performance, especially in patients with impairment. - Hepatic function: adjust use in patients with liver disease. - Discontinuation: avoid abrupt cessation to prevent seizure worsening. - Patient counseling: advise about dizziness and driving safety. - Store at room temperature: keep in the original container, protect from moisture and direct sunlight.

Lacosamide can interact with other medicines, requiring careful management.

Major Interactions (Avoid): - Carbamazepine: may reduce lacosamide plasma levels, decreasing efficacy. - Phenytoin: may increase risk of cardiac conduction abnormalities.

Moderate Interactions (Monitor Closely): - CYP2C19 inhibitors (e.g., fluconazole): may raise lacosamide concentrations. - Other antiepileptics (e.g., valproate): may enhance central nervous system side effects. - Concomitant QT‑prolonging drugs: monitor cardiac rhythm for additive effects.